1. A curable powder composition comprising:
(a) at least one material having the structure of Formula I:
\u2003wherein R1, is an organic radical having 6 to 25 carbon atoms; each R2 is independently a multivalent hydrocarbon group having 1 to 20 carbon atoms; Y is
\u2003each R3 and R4 are independently alkyl or aryl groups having 1 to 8 carbon atoms; each Z is independently oxygen or nitrogen; R5 is absent when Z is oxygen and R5 is hydrogen, an alkyl or aryl group having 1 to 20 carbon atoms, or (Y)a\u2014R2 \u2014 when Z is nitrogen; a is at least 1; b is 1 to 3; and
(b) at least one epoxy-containing resin andor at least one siloxane-containing resin; and when the epoxy-containing resin is a polyepoxide, Z is nitrogen, R2 is alkylene having 1 to 4 carbons, R3 and R4 are alkyl groups having 1 to 4 carbons, the composition cures in the absence of any additional component.
2. The curable powder composition of claim 1, wherein said composition cures at a temperature of between 80\xb0 C. and 125\xb0 C.
3. The curable powder composition of claim 2, wherein said composition cures at a temperature of between 105\xb0 C. and 120\xb0 C.
4. The curable powder composition of claim 1, wherein said composition cures at a temperature greater than 125\xb0 C.
5. The curable powder composition of claim 1, wherein Z is nitrogen, and R5 is hydrogen.
6. The curable powder composition of claim 5, wherein R1 is 1,3,3-trimethylcyclohexylmethylene or 1,1,3,3-tetramethylcyclohexylene.
7. The curable powder composition of claim 5, wherein R2 is n-propylene.
8. The curable powder composition of claim 5, wherein R3 and R4 are methyl.
9. The curable powder composition of claim 1, wherein (a) is present in an amount ranging from about 0.5 to 10 weight percent, and (b) is present in an amount ranging from about 20 to about 90 weight percent, with weight percent being based upon total weight of the composition.
10. The curable powder composition of claim 9, wherein (a) is present in an amount ranging from about 3 to 5 weight percent, and (b) is present in an amount ranging from about 30 to about 60 weight percent, with weight percent being based upon total weight of the composition.
11. The curable powder composition of claim 1, wherein the epoxy-containing resin comprises polyepoxide and the powder composition cures in the absence of any additional component.
12. The curable powder composition of claim 1, wherein the resin is a siloxane-containing resin.
13. A cured coating layer comprising:
(a) a material having Formula I:
\u2003wherein R1 is an organic radical having 6 to 25 carbon atoms; each R2 is independently a multivalent hydrocarbon group having 1 to 20 carbon atoms; Y is
\u2003each R3 and R4 are independently alkyl or aryl groups having 1 to 8 carbon atoms; each Z is independently oxygen or nitrogen; R5 is absent when Z is oxygen and R5 is hydrogen, an alkyl or aryl group having 1 to 20 carbon atoms, or (Y)a\u2014R2\u2014 when Z is nitrogen; a is at least 1; b is 1 to 3; and
(b) at least one epoxy-containing resin andor at least one siloxane-containing resin;
wherein the epoxy andor the siloxane has reacted with itself during cure and said cure takes place in the absence of an additional crosslinker.
14. A method for initiating self-cure of an epoxy-containing resin andor a siloxane-containing resin comprising adding to a composition comprising said resin(s) a catalyst having the structure:
wherein R1 is an organic radical having 6 to 25 carbon atoms; each R2 is independently a multivalent hydrocarbon group having 1 to 20 carbon atoms; Y is
each R3 and R4 are independently alkyl or aryl groups having 1 to 8 carbon atoms; each Z is independently oxygen or nitrogen; R5 is absent when Z is oxygen and R5 is hydrogen, an alkyl or aryl group having 1 to 20 carbon atoms, or (Y)a \u2014R2\u2014 when Z is nitrogen; a is at least 1; b is 1 to 3.
15. The curable powder composition of claim 1, wherein R2 is alkylene.
16. The curable powder composition of claim 1, wherein R3 and R4 are alkyl.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for identifying metastases in a subject comprising detecting nucleic acid hypermethylation of one or more genes in one or more samples, wherein detecting nucleic acid hypermethylation identifies metastases.
2. The method of claim 1, wherein the sample comprises cells or tissues selected from the group consisting of: tumor, lymph nodes, bone marrow and blood.
3-5. (canceled)
6. A method for identifying metastases in a subject comprising detecting nucleic acid hypermethylation of one or more genes in tumor tissue or lymph node, wherein the genes are selected from the group consisting of: genes involved in tumor suppression, DNA repair, apoptosis, anti-proliferation, ras signaling, adhesion, differentiation, development, and cell cycle regulation, wherein detecting nucleic acid hypermethylation identifies metastases.
7-11. (canceled)
12. A method for identifying micrometastases in a subject comprising detecting nucleic acid hypermethylation of at least one or more genes in a sample comprising tumor and lymph nodes, wherein the sample genes are selected from the group consisting of: H-cadherin, p16, APC, RASSF1A, MGMT, DAPK, and ASC, and wherein detecting nucleic acid methylation identifies micrometastases.
13. The method of claim 12, wherein hypermethylation of at least two of the genes is detected.
14. The method of claim 11, wherein at least two of the genes are selected from p-16 and H-cadherin, H-cadherin and APC, APC and p16, or RASSf1A and p16.
15. The method of claim 1 claim 1, wherein the detection of metastases is used to detect or diagnose a proliferative disease.
16-19. (canceled)
20. A method for detecting or diagnosing a proliferative disease in a subject comprising detecting nucleic acid hypermethylation of one or more genes in one or more samples, wherein detecting nucleic acid hypermethylation is used to detect or diagnose a proliferative disease.
21. A method for predicting the recurrence of a proliferative disease in a subject comprising: detecting nucleic acid hypermethylation of one or more genes wherein detecting nucleic acid hypermethylation of one or more genes is a predictor of the recurrence of a proliferative disease.
22. The method of claim 21, wherein hypermethylation of one or more genes is detected in tumor or lymph nodes.
23. (canceled)
24. A method for staging or re-staging a proliferative disease in a subject comprising: detecting nucleic acid hypermethylation of one or more genes wherein detecting nucleic acid hypermethylation is used for staging or re-staging a proliferative disease.
25-26. (canceled)
27. A method for determining the prognosis of a subject suffering from a proliferative disease comprising: detecting nucleic acid hypermethylation of one or more genes wherein the detection of nucleic acid hypermethylation is used for determining the prognosis of a subject suffering from a proliferative disease.
28-34. (canceled)
35. A method for detecting or diagnosing a proliferative disease in a subject comprising:
extracting nucleic acid from one or more cell or tissue samples;
detecting nucleic acid hypermethylation of one or more genes in the sample; and
identifying the nucleic acid hypermethylation state of one or more genes, wherein nucleic acid hypermethylation of genes indicates a proliferative disease.
36. A method for predicting the recurrence of a proliferative disease in a subject comprising:
extracting nucleic acid from one or more cell or tissue samples;
detecting nucleic acid hypermethylation of one or more genes in the sample; and
identifying the nucleic acid hypermethylation state of one or more genes, wherein nucleic acid hypermethylation of genes is indicative of the recurrence of a proliferative disease.
37. A method for staging or re-staging a proliferative disease in a subject comprising:
extracting nucleic acid from one or more cell or tissue samples;
detecting nucleic acid hypermethylation of one or more genes in the sample; and
identifying the nucleic acid hypermethylation state of one or more genes, wherein nucleic acid hypermethylation of genes is used for staging or re-staging of a proliferative disease.
38-42. (canceled)
43. A method of treating a subject having or at risk for having a proliferative disease comprising:
identifying nucleic acid hypermethylation of one or more genes, where nucleic acid hypermethylation indicates having or a risk for having a proliferative disease; and
administering to the subject a therapeutically effective amount of a demethylating agent,
thereby treating a subject having or at risk for having a proliferative disease.
44-54. (canceled)
55. A method of identifying an agent that de-methylates hypermethylated nucleic acid comprising:
identifying one or more cell or tissue samples with hypermethylated nucleic acid;
extracting the hypermethylated nucleic acid;
contacting the nucleic acid with one or more nucleic acid de-methylating candidate agents and a control agent;
identifying the nucleic acid hypermethylation state, wherein nucleic acid de-methylation of genes in the sample by the candidate agent compared to the control indicates a demethylating agent,
thereby identifying an agent that de-methylates hypermethylated nucleic acid.
56-70. (canceled)
71. A kit for identifying the nucleic acid hypermethylation state of one or more genes comprising gene specific primers for use in polymerase chain reaction (PCR), and instructions for use.
72. A kit for detecting metastases by detecting nucleic acid hypermethylation of one or more genes, the kit comprising gene specific primers for use in polymerase chain reaction (PCR), and instructions for use.
73. hThe kit of claim 72, wherein the metastases are micrometastases.
74-82. (canceled)